No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NRIX240517C15000
- 0.62
- -0.08-11.43%
15min DelayClose May 9 15:58 ET
0.65High0.62Low
0.65Open0.70Pre Close2 Volume230 Open Interest15.00Strike Price127.00Turnover138.18%IV12.72%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.62Time Value100Contract SizeAmericanOptions Type0.4012Delta0.1365Gamma19.24Leverage Ratio-0.0722Theta0.0011Rho7.72Eff Leverage0.0079Vega
Intraday
- 5D
- 1D
News
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat
Nurix Therapeutics(NRIX.US) Officer Sells US$44,878.17 in Common Stock
$Nurix Therapeutics(NRIX.US)$ Officer van Houte Hans sold 3,499 shares of common stock on May 2, 2024 at an average price of $12.826 for a total value of $44,878.17.Source: Announcement What is statem
Analysts' Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Nurix Therapeutics (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Nurix Therapeutics (NASDAQ:NRIX) Climbs Higher After Beating Expectations
Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler
Comments
$Nurix Therapeutics(NRIX.US$ Nurix Therapeutics Inc - Commenced an Underwritten Public Offering of $125 Mln of Its Common Stock
2
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
Investors may believe the company's poor revenue performance won't improve, causing a low P/S ratio. The company's future revenue growth is expected to be weaker than the industry average, causing discomfort among shareholders.
1
Investors remain skeptical of Nurix Therapeutics' future despite strong performance, with its forecasted growth rate much lower than the industry's 235%. Current P/S ratio hints that expected growth may not justify a higher P/S, needing a turnaround to satisfy investor sentiment.
Read more